<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566787</url>
  </required_header>
  <id_info>
    <org_study_id>CP2003-1</org_study_id>
    <nct_id>NCT00566787</nct_id>
  </id_info>
  <brief_title>Concomitant Treatment of Permanent Atrial Fibrillation</brief_title>
  <acronym>RESTORE SR</acronym>
  <official_title>A Prospective, Multi-center Study With Case Matched Controls to Evaluate the Safety and Efficacy of the AtriCure Bipolar System for the Treatment of Continuous Atrial Fibrillation as Adjunct Therapy to Elective Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <brief_summary>
    <textblock>
      RESTORE-SR study is a multi-center, prospective, nonrandomized study with case matched
      concurrent controls to evaluate the safety and efficacy of the AtriCure Bipolar System
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint is the proportion of treated patients who are free of atrial fibrillation without the need for anti-arrhythmic agents at the six-month follow-up visit.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety endpoint is the occurrence of serious adverse events that are considered to be associated with the Maze procedure.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy endpoint is the proportion of patients in the treatment group who are free of atrial fibrillation independent of the need for anti-arrhythmic drugs.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary safety endpoints are: total cross clamp time, total time on bypass, length of hospital stay (days), and length of ICU stay (hours)</measure>
    <time_frame>Discharge</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System</intervention_name>
    <description>Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female subject between 18 to 80 years of age

          2. Subject is scheduled to undergo elective cardiac surgical procedure(s) to be performed
             on cardiopulmonary bypass including:

               -  coronary artery bypass and/or

               -  mitral valve surgery (repair or replacement)

               -  aortic valve surgery (repair or replacement)

               -  tricuspid valve surgery (repair or replacement)

          3. Left Ventricular Ejection Fraction â‰¥ 30%

          4. Subject is willing and able to provide written informed consent

          5. Subject has a life expectancy of at least 2 years

          6. Subject is willing and able to return for scheduled follow-up visits

          7. TREATMENT SUBJECTS ONLY: Subject has a 3 month documented history of continuous atrial
             fibrillation

          8. CONTROL SUBJECTS ONLY: Subject is not in atrial fibrillation at time of surgery

        Exclusion Criteria:

          1. Lone AF without indication(s) for concomitant CABG and/or mitral valve surgery, aortic
             valve surgery, tricuspid valve surgery or double valve surgery

          2. Prior cardiac surgery (Redo -including previous ablation)

          3. Patient requires atrial septal defect repair or any other concomitant open-heart
             procedure, other than CABG and/or mitral valve surgery; aortic valve surgery,
             tricuspid valve surgery or double valve surgery

          4. Serum creatinine concentration greater than 2.0 mg/dl

          5. Class IV NYHA heart failure symptoms and/or Class IV CCS anginal symptoms

          6. Prior history of cerebrovascular accident within 6 months or at any time if there is
             residual neurologic deficit

          7. Active infection

          8. Known carotid artery stenosis greater than 80%

          9. Severe peripheral arterial occlusive disease defined as claudication with minimal
             exertion

         10. A known drug and/or alcohol addiction

         11. Mental impairment or other conditions which may not allow the the subject to
             understand the nature, significance and scope of the study

         12. Pregnancy or desire to get pregnant within 12 months of study enrollment

         13. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Marc Gillinov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>99220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Medical Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>afib</keyword>
  <keyword>racing heart</keyword>
  <keyword>cabg</keyword>
  <keyword>valve</keyword>
  <keyword>ablation</keyword>
  <keyword>bipolar</keyword>
  <keyword>radiofrequency</keyword>
  <keyword>rf</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

